World Health Organization Sounds Warning Over Severe Lack of Weight-Loss Injections

Under 10% of patients eligible to benefit from obesity jabs like Wegovy are able to get them, warns the global health agency as it publishes its initial recommendations on the medications.

Given over a billion people worldwide now living with obesity, it is advocating for broader and more equitable availability to these injectable treatments.

Based on projections, more than two billion will be obese by 2030 without intervention.

"Our latest guidance recognises that obesity is a long-term condition that can be addressed with comprehensive and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and distribution challenges are significant barriers to universal access to the injections that can assist patients in reducing considerable weight, explains the agency.

Skinny Jab Scarcity

Despite the current most optimistic case, the manufacturing of these medications could only cover approximately 100 million people – less than 10% of the global need, as stated by the health organization.

The recommendation calls on nations and manufacturers to widen access, via strategies including voluntary licensing.

Exclusive production rights on semaglutide – the main ingredient of the drug Wegovy – is scheduled to end in several nations in 2026.

How Weight-Loss Injections Function

These medications imitate a body's own hormone to reduce digestion speed, suppress the appetite and boost feelings of fullness so individuals reduce food intake.

Individuals typically see weight reduction after several weeks of commencing the once-weekly jabs.

Research points to people may see weight return after a year of stopping the drug, when their typical hunger return.

To be above a healthy weight increases your likelihood for contracting medical conditions, such as type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.

Obesity impacts people in countries worldwide and was associated with millions of fatalities worldwide in 2024, per the WHO.